ISSN 1673-3770 CN 37-1437/R
山东大学耳鼻喉眼学报 ›› 2016, Vol. 30 ›› Issue (4): 10-14.doi: 10.6040/j.issn.1673-3770.0.2016.280
张革化,李文婷
ZHANG Gehua, LI Wenting
中图分类号:
| [1] Zhang Y, Zhang L. Prevalence of allergic rhinitis in china[J]. Allergy Asthma Immunol Res, 2014, 6(2):105-113. [2] Zuberbier T, Lotvall J, Simoens S, et al. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2)LEN review[J]. Allergy, 2014, 69(10):1275-1279. [3] Bousquet J, Khaltaev N, Cruz A A, et al. Allergic rhinitis and its impact on asthma(ARIA)2008 update(in collaboration with the World Health Organization, GA2LEN and AllerGen)[J]. Allergy, 2008, 63(Suppl 86):8-160. [4] Brozek J L, Bousquet J, Baena-Cagnani C E, et al. Allergic rhinitis and its impact on asthma(ARIA)guidelines: 2010 revision[J]. J Allergy Clin Immunol, 2010, 126(3):466-476. [5] Okubo K, Kurono Y, Fujieda S, et al. Japanese Guideline for Allergic Rhinitis 2014[J]. Allergology International, 2014, 63(3):357-375. [6] Seidman M D, Gurgel R K, Lin S Y, et al. Clinical practice guideline: allergic rhinitis[J]. Otolaryngol Head Neck Surg, 2015, 152(Suppl 1):S1-S43. [7] 中华医学会耳鼻咽喉头颈外科学分会鼻科学组,中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组. 变应性鼻炎诊断和治疗指南(2015年,天津)[J]. 中华耳鼻咽喉头颈外科杂志,2016, 51(1):6-24. [8] Anolik R. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2008, 100(3):264-271. [9] Rodrigo G J, Neffen H. Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review[J]. Clin Exp Allergy, 2011, 41(2):160-170. [10] Penagos M, Compalati E, Tarantini F, et al. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials[J]. Allergy, 2008, 63(10):1280-1291. [11] Herman H. Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost[J]. Am J Rhinol, 2007, 21(1):70-79. [12] Bielory L, Chun Y, Bielory B P, et al. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis[J]. Allergy, 2011, 66(5):686-693. [13] Ratner P H, Meltzer E O, Teper A. Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis[J]. Int J Pediatr Otorhinolaryngol, 2009, 73(5):651-657. [14] Tripathy I, Levy A, Ratner P, et al. HPA axis safety of fluticasone furoate nasal spray once daily in children with perennial allergic rhinitis[J]. Pediatr Allergy Immunol, 2009, 20(3):287-294. [15] Schenkel E J, Skoner D P, Bronsky E A, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray[J]. Pediatrics, 2000, 105(2):E22. [16] Karaki M, Akiyama K, Mori N. Efficacy of intranasal steroid spray(mometasone furoate)on treatment of patients with seasonal allergic rhinitis: comparison with oral corticosteroids[J]. Auris Nasus Larynx, 2013, 40(3):277-281. [17] Wheatley L M, Togias A. Clinical practice. Allergic rhinitis[J]. N Engl J Med, 2015, 372(5):456-463. [18] Horak F, Zieglmayer U P, Zieglmayer R, et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy[J]. Curr Med Res Opin, 2006, 22(1):151-157. [19] Kaliner M A, Berger W E, Ratner P H, et al. The efficacy of intranasal antihistamines in the treatment of allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2011,106(Suppl 2):S6-S11. [20] Benninger M, Farrar J R, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class[J]. Ann Allergy Asthma Immunol, 2010, 104(1):13-29. [21] Meltzer E O, Bernstein D I, Prenner B M, et al. Mometasone furoate nasal spray plus oxymetazoline nasal spray: short-term efficacy and safety in seasonal allergic rhinitis[J]. Am J Rhinol Allergy, 2013, 27(2):102-108. [22] Cruz A A, Popov T, Pawankar R, et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA2LEN[J]. Allergy, 2007, 62(Suppl 84):1-41. [23] Bousquet J, Schünemann H J, Samolinski B, et al. Allergic rhinitis and its impact on asthma(ARIA): achievements in 10 years and future needs[J]. J Allergy Clin Immunol, 2012, 130(5):1049-1062. [24] Lohia S, Schlosser R J, Soler Z M. Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a meta-analysis[J]. Allergy, 2013, 68(5):569-579. [25] Seidman M D, Gurgel R K, Lin S Y, et al. Clinical practice guideline: allergic rhinitis executive summary[J]. Otolaryngol Head Neck Surg, 2015, 152(2):197-206. [26] Ratner P H, Andrews C, Martin B, et al. A study of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol in patients with seasonal allergic rhinitis from mountain cedar pollen[J]. Allergy Asthma Proc, 2012, 33(1):27-35. [27] Leach C L, Kuehl P J, Chand R, et al. Nasal deposition of HFA-beclomethasone, aqueous fluticasone propionate and aqueous mometasone furoate in allergic rhinitis patients[J]. J Aerosol Med Pulm Drug Deliv, 2015, 28(5):334-340. [28] Bousquet J, Bachert C, Bernstein J, et al. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02(a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system)fills the gaps[J]. Expert Opin Pharmacother, 2015, 16(6):913-928. [29] Cavet M E, Volhejn S, Harrington K L, et al. Anti-allergic effects of mapracorat, a novel selective glucocorticoid receptor agonist, in human conjunctival fibroblasts and epithelial cells[J]. Mol Vis, 2013, 19:1515-1525. [30] Faria R, Mckenna C, Palmer S. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis[J]. Value Health, 2014, 17(8):772-782. |
| [1] | 王坛,武珂,李连庆,宫丽丽. 皮下免疫治疗注射后出现全身不良反应的伴发因素及处理[J]. 山东大学耳鼻喉眼学报, 2018, 32(5): 71-74. |
| [2] | 卢汉桂,林歆胜,姚丹勉,魏永新,李创伟. 变应性鼻炎大鼠IL-35的表达及对辅助性T细胞免疫调节的影响[J]. 山东大学耳鼻喉眼学报, 2018, 32(5): 66-70. |
| [3] | 浦洪波,杜晓东. 无锡地区2 000例变应性鼻炎变应原检测结果分析[J]. 山东大学耳鼻喉眼学报, 2018, 32(4): 105-107. |
| [4] | 黄凯丰. 糖皮质激素短疗程雾化吸入对嗜酸粒细胞性鼻窦炎伴鼻息肉患者鼻部症状及肾上腺皮质功能的影响[J]. 山东大学耳鼻喉眼学报, 2018, 32(4): 28-31. |
| [5] | 吴湘萍. 患者管理方式对变应性鼻炎舌下含服粉尘螨滴剂疗效的影响[J]. 山东大学耳鼻喉眼学报, 2018, 32(3): 68-72. |
| [6] | 陈鸣,俞雪飞. 浅谈伴有变应性鼻炎的慢性鼻窦炎的治疗[J]. 山东大学耳鼻喉眼学报, 2018, 32(3): 18-22. |
| [7] | 李华斌, 赖玉婷. 慢性鼻-鼻窦炎的发病机制及诊疗进展[J]. 山东大学耳鼻喉眼学报, 2018, 32(3): 4-9. |
| [8] | 谢洪彬,杨美娜,陈青山,刘旭阳,樊宁. IgG4相关性眼病伴继发性青光眼病例分析[J]. 山东大学耳鼻喉眼学报, 2018, 32(2): 99-102. |
| [9] | 高进良,年婉清,李烁. 鼻内镜手术联合鼻用糖皮质激素治疗腺样体肥大性[J]. 山东大学耳鼻喉眼学报, 2018, 32(2): 38-42. |
| [10] | 李松,王宗贵,杨景朴,张竹萍. 鼻内镜下翼管神经切断术进展[J]. 山东大学耳鼻喉眼学报, 2018, 32(1): 72-76. |
| [11] | 郅莉莉,宋道亮. 嗜酸性粒细胞及IL5在上颌窦后鼻孔息肉与鼻息肉中表达的差异[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 43-46. |
| [12] | 万文锦,王文,程雷. 尘螨变应性鼻炎皮下免疫治疗与舌下免疫治疗的荟萃分析[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 103-108. |
| [13] | 史丽,赵莉,张红萍. 变应性鼻炎的长期抗炎治疗[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 9-12. |
| [14] | 刘静. 基于整体观念变应性鼻炎的中医辨证论治[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 28-30. |
| [15] | 程雷,钱俊俊,田慧琴. 变应性鼻炎研究的若干进展[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 1-3. |
|
||